Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024 Programme PBC (sous...
PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track...
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 PBC program (licensed to Ipsen): Ipsen to present new...
GENFIT : Information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie s’élevant à 96,0 millions d’euros au 30...
Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024...
GENFIT Reports Third Quarter 2024 Financial Information Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in...
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA...
GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a...
GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant...
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update Cash and cash equivalents totaled €61.6 million as of June...
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in...
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis Lille (France), Cambridge...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage...
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관